IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of “Buy” by Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have been assigned a consensus rating of “Buy” from the seventeen research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $229.1250.

A number of equities research analysts recently weighed in on IQV shares. Evercore reissued an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a research report on Thursday, February 5th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. BMO Capital Markets set a $250.00 target price on IQVIA in a research report on Friday, February 6th. Jefferies Financial Group dropped their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Finally, Truist Financial reduced their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th.

Institutional Trading of IQVIA

A number of large investors have recently bought and sold shares of IQV. Claret Asset Management Corp increased its stake in IQVIA by 1.1% in the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after purchasing an additional 49 shares during the period. Versant Capital Management Inc increased its position in IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after acquiring an additional 53 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. raised its stake in IQVIA by 3.3% during the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 58 shares during the last quarter. Quadrant Capital Group LLC grew its stake in shares of IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after purchasing an additional 60 shares during the last quarter. Finally, Brookstone Capital Management grew its stake in shares of IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $169.05 on Friday. The stock’s 50-day simple moving average is $188.18 and its 200-day simple moving average is $205.38. The firm has a market capitalization of $28.69 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 1.60 and a beta of 1.39. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same period in the prior year, the firm posted $3.12 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts forecast that IQVIA will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.